Mesoblast (MESO) EBITDA Margin (2014 - 2023)

Mesoblast has reported EBITDA Margin for 10 years, with the latest figure at 943.77% in Q2 2023.

• Quarterly EBITDA Margin fell 94814.0% year-over-year to 943.77% in Q2 2023, while the trailing twelve-month figure through Jun 2023 was 573.74% (down 309.0% YoY) and the FY2025 annual result came in at 360.79%, up 63538.0% from the prior year.
• EBITDA Margin fell to 943.77% in Q2 2023 per MESO's latest filing, from 153.48% in the prior quarter.
• Over five years, EBITDA Margin peaked at 4.37% in Q2 2022 and troughed at 2306.24% in Q1 2019.
• A 5-year average of 823.91% and a median of 827.37% in 2021 frame the typical range for EBITDA Margin.
• The sharpest annual moves came in 2019 and 2020: EBITDA Margin soared 188278 bps in 2019, then slumped 143079 bps in 2020.
• Over 5 years, EBITDA Margin stood at 1180.85% in 2019, then grew by 18 bps to 964.93% in 2020, then grew by 8 bps to 888.15% in 2021, then climbed by 27 bps to 650.05% in 2022, then sank by 45 bps to 943.77% in 2023.
• According to Business Quant data, EBITDA Margin over the past three periods registered 943.77%, 153.48%, and 650.05% for Q2 2023, Q1 2023, and Q4 2022 respectively.